VERFAHREN FÜR IMMUNOGENE MODULATION

Patent europeic · EP3417289 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP3417289
Numer da la dumonda
EP17753857
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
16-02-2017
Publitgà
26-12-2018
Concedì
23-12-2020
Stritgà
28-02-2021
Motiv
Taxa annuala betg pajada
Classas IPC
G01N 33/50 (2006.01)
G01N 33/68 (2006.01)
Prioritad
US 201662297751 P 19.02.2016
Dumonda PCT
PCT/US2017/018214 16.02.2017
Publicaziun PCT
WO2017/143092 24.08.2017
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 03-11-2021

    Midada

    Published in Swissreg on 03.11.2021

  2. 22-09-2021

    Stritgà, taxa betg pajada

    Published in Swissreg on 22.09.2021

  3. 23-12-2020

    Concedì

    Published in Swissreg on 23.12.2020

Partidas

Possessur

NantCell, Inc.

9920 Jefferson Boulevard, Culver City, CA 90232, US

Nant Holdings IP, LLC

9920 Jefferson Boulevard, Culver City, CA 90232, US

Inventur

SOON-SHIONG, Patrick

Culver City, CA 90232, US

NIAZI, Kayvan

Culver City, CA 90232, US

RABIZADEH, Shahrooz

Culver City, CA 90232, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.